Related Experiment Video
Updated: Apr 24, 2026
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma
Francesco Massari1, Chiara Ciccarese, Antonio Bentito Porcaro
11Medical Oncology, Azienda Ospedaliera Universitaria Integrata di Verona AOUI, University of Verona 2Urologic Clinic, Department of Oncological and Surgical Sciences, University of Verona 3Department of Medical, Surgical and Odontoiatric Science, University of Milan, Italy and Fondazione Instituto di Ricovero e cura a carattere Scientifico (IRCCS), Cà Grada Policlinico, Milan 4Anatomic Pathology, Azienda Ospedaliera 'Mellino Mellini' Hospital Chiari, Bergamo 5Department of Pathology and Diagnostic, University of Verona 6Urologic Clinic, Department of Surgical Sciences, University of Padua 7Urologic Clinic, Azienda Ospedaliera Universitaria, University of Udine 8Department of Surgical and Medical Physiopathology and Transplantation, University of Milan and Fondazione Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Cà Granda Policlinico, Italy 9Department of Pathology and Laboratory Medicine, Indiana University, IN, United States.
Abstract:
We sought to evaluate the expression of HSP27 and HSP90 chaperones in renal cell carcinomas as a target for cancer therapeutics.A total of 127 clear cell renal cell carcinomas stratified according to the Mayo Clinic SSIGN (size, staging, grading, and necrosis) risk groups (good, 1; poor, 5) and 20 cases with metastases, were available. Immunostaining for both HSP27 and HSP90 was performed on tissue microarrays. Results were detailed per scorable arrays per SSIGN risk groups.Immunolabelling for HSP90 and HSP27 was seen in 109 of 127 (86%) and 114 of 127 (89%) cases, respectively. HSP90 scored 4.9 in 32 cases risked SSIGN 1, 3.5 in 41 cases SSIGN 2, 4.8 in 11 cases SSIGN 3, 4.2 in 22 cases SSIGN 4, and 5.0 in three cases SSIGN 5. HSP27 scored 4.6 in 33 risked SSIGN 1, 3.1 in 43 SSIGN 2, 2.6 in 11 SSIGN 3, 3.6 in 24 SSIGN 4, and 2.7 in three SSIGN 5. Metastases ranged from 2.9-5.0. A trend of increasing value for HSP90 was observed when comparing SSIGN 1-2 versus SSIGN 3-5 risk groups (4.2 versus 4.6 mean values; p = 0.06); no difference has been observed for HSP27 (3.8 to 3.9; p = 0.08).A score modulation of HSPs is observed in renal cell carcinoma and may affect the efficacy of targeted therapy.
